139 related articles for article (PubMed ID: 31474863)
1. A Phase I, Randomized, Single-Dose Study Evaluating the Biosimilarity of TAB008 to Bevacizumab in Healthy Volunteers.
Wang J; Qi L; Liu L; Wang Z; Chen G; Wang Y; Liu X; Liu Y; Liu H; Tong Y; Liu C; Lei C; Wang X
Front Pharmacol; 2019; 10():905. PubMed ID: 31474863
[No Abstract] [Full Text] [Related]
2. Bevacizumab biosimilar candidate TAB008 compared to Avastin
Lu S; Qin S; Zhou Z; Chen J; Gu K; Sun P; Pan Y; Yu G; Ma K; Shi J; Sun Y; Yang L; Chen P; Liu A; He J
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5907-5914. PubMed ID: 36595042
[TBL] [Abstract][Full Text] [Related]
3. A phase I study comparing the biosimilarity of the pharmacokinetics and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection with Avastin
Li H; Zhao X; Xie J; Zhu X; Su Y; He C; Ding J; Zhu M; Xu Y; Wang Y; Shan R; Liu B; Ding Y; Liu Y; Zhou H; Xie Y
BMC Pharmacol Toxicol; 2023 May; 24(1):36. PubMed ID: 37245022
[TBL] [Abstract][Full Text] [Related]
4. A Randomized, Double-Blind, Single-Dose Study Comparing the Biosimilarity of HOT-1010 With Bevacizumab (Avastin®) in Chinese Healthy Male Subjects.
Huang K; Que L; Ding Y; Chu N; Qian Z; Shi Y; Qin W; Li Z; Chen Y; Gu X; Wang J; Zhang L; Zhang J; Zhu X; Yang Y; Tang Y; He Q
Front Pharmacol; 2021; 12():694375. PubMed ID: 34220519
[No Abstract] [Full Text] [Related]
5. A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects.
Liu YN; Huang J; Guo C; Yang S; Ye L; Wu ST; Zhang XF; Yang XY; Han CC; Pei Q; Huang L; He QN; Yang GP
Cancer Chemother Pharmacol; 2020 Mar; 85(3):555-562. PubMed ID: 31907645
[TBL] [Abstract][Full Text] [Related]
6. A Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of SCT510 to Bevacizumab (Avastin
Wu J; Wu G; Xie L; Lv D; Xu C; Zhou H; Wu L; Zhang J; Shentu J
Drugs R D; 2023 Jun; 23(2):175-183. PubMed ID: 37247166
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of LY01008, a candidate bevacizumab biosimilar, with its reference product Avastin® in healthy Chinese male subjects.
Zhou R; Yang J; Liu Y; Zhang Q; Lu C; Tang K; Li X; Tang W; Gao E; Wu C; Dou C; Hu W
Expert Opin Biol Ther; 2022 Feb; 22(2):263-269. PubMed ID: 34913787
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial comparing LY01011, biosimilar candidate, with the reference product denosumab (Xgeva®) in healthy Chinese subjects.
Ding Y; Liu Y; Dou C; Guo S
J Bone Oncol; 2023 Oct; 42():100499. PubMed ID: 37701913
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, parallel-group, single‑dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men.
Singh I; Patel R; Patel A; Jose V
Cancer Chemother Pharmacol; 2020 Aug; 86(2):193-202. PubMed ID: 32627073
[TBL] [Abstract][Full Text] [Related]
10. Phase I, randomized, double-blind, single-dose study to assess the pharmacokinetics, safety, and immunogenicity of the proposed biosimilar SCT630 and adalimumab in healthy Chinese subjects.
Liu L; Qi L; Lei C; Wang Y; Zhang W; Liu Y; Li P; Bai H; Li Y; Li Y; Liu J; Xie L; Wang X
Int Immunopharmacol; 2022 May; 106():108599. PubMed ID: 35193054
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, Tolerability, Safety, and Immunogenicity of LY01008 and Bevacizumab (Avastin®) in Healthy Chinese Subjects.
Xie L; Zhu Y; Liang Z; Zhao Y; Zhou S; Chen J; Zhang H; Ding S; Wang L; Shao F
Eur J Drug Metab Pharmacokinet; 2022 May; 47(3):309-317. PubMed ID: 35112328
[TBL] [Abstract][Full Text] [Related]
12. A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin
Wu X; Wynne C; Xu C; Gan Y; Wang C; Thomas BE; Yu JC; Li S; Zhang L
BioDrugs; 2019 Jun; 33(3):335-342. PubMed ID: 31016568
[TBL] [Abstract][Full Text] [Related]
13. A comparative pharmacokinetic study of DRL_BZ, a candidate biosimilar of bevacizumab, with Avastin
Wynne C; Schwabe C; Batra SS; Lopez-Lazaro L; Kankanwadi S
Br J Clin Pharmacol; 2018 Oct; 84(10):2352-2364. PubMed ID: 29943831
[TBL] [Abstract][Full Text] [Related]
14. A randomized, single-dose, pharmacokinetic equivalence study comparing MB02 (proposed biosimilar) and reference bevacizumab in healthy Japanese male volunteers.
Eto T; Karasuyama Y; González V; Del Campo García A
Cancer Chemother Pharmacol; 2021 Oct; 88(4):713-722. PubMed ID: 34269848
[TBL] [Abstract][Full Text] [Related]
15. A phase I, randomized, double-blinded, single-dose study evaluating the pharmacokinetic equivalence of the biosimilar IBI305 and bevacizumab in healthy male subjects
.
Zhang H; Zhu X; Wei H; Li C; Chen H; Li X; Wu M; Liu J; Chen G; Zhou H; Zheng S; Ding Y
Int J Clin Pharmacol Ther; 2019 Mar; 57(3):167-174. PubMed ID: 30663977
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study.
Li S; Wu X; Li N; Cao G; Wang J; Chen Y; Li S; He J; Wu J; Yang H; Lin K; Qiu C; Liu A; Zhou H; Adrian F; Schweizer L; Zhang W; Gu J; Zhang J
Front Pharmacol; 2023; 14():1117293. PubMed ID: 37332355
[No Abstract] [Full Text] [Related]
17. A Randomized Phase 1 Pharmacokinetic Study Comparing the Potential Biosimilar LRG201902 With Liraglutide (Victoza
Mai G; Fan L; Li M; Zhang P; Gan C; Huang Q; Shentu J
Front Pharmacol; 2020; 11():610880. PubMed ID: 33584289
[No Abstract] [Full Text] [Related]
18. A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers.
Sinn A; García-Alvarado F; Gonzalez V; Huerga C; Bullo F
Br J Clin Pharmacol; 2022 Mar; 88(3):1063-1073. PubMed ID: 34374114
[TBL] [Abstract][Full Text] [Related]
19. LZM008, a proposed tocilizumab biosimilar: Pharmacokinetics, safety, and immunogenicity profiles compared with ACTEMRA
Cao G; Wang J; He J; Hu Y; Yang H; Que L; Gu X; Yu J; Wu X; Wu J; Fang W; He Q; Zhang J
Front Pharmacol; 2023; 14():1111893. PubMed ID: 37081963
[No Abstract] [Full Text] [Related]
20. A Phase I Clinical Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of GB221 Injection and Trastuzumab (Herceptin
Zhu Y; Li C; Chen L; Liu H; Ou L; Li T; Wang X; Wang T; Tian J; Liang X; Hu Z; Zhan Y; Xiao S; Wang X; Li Y; He J; Zheng Q; Song H; Li X; Fang Y
Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):383-392. PubMed ID: 38564097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
